Bob_LobLaw,
X Master and Karlchen are correct about Linda maintaining control to get this to patients. Also, the UK has had the fastest path forward to reimbursement through Specials and then approval because of National Priority and the influence of Dr. Ashkan. The multi continent strategy took into consideration the influence of big pharma on “the process” and there is a much smaller “in house” initial investment related to cash needed before revenue generation and cash flow for fitting out “the model” that reduces the amount of dilution needed than paying someone else to do it before you have revenue.
Linda looks at everything she does as lawyer, scientist and business owner. Her strengths are law and business but she also has very good grasp on the overall science. Unless a person can look at her decisions from the same perspective they will fail to understand her moves and think that there are better business moves, better communication moves, better ways to advance the science etc. The bottom line is that Linda knows how to leverage every exception, every opportunity and situations which seem otherwise beyond her control like buying time for manufacturing while regulators get their act together and the patent office gets taken to school ; ). Best wishes.
Market Data 
Markets 
AI
